Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink

DECLARE-TIMI 58: Participants’ baseline characteristics

(2018) Itamar Raz et al.   DIABETES OBESITY & METABOLISM

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes

(2017) Rury R. Holman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

(2017) Bruce Neal et al.   NEW ENGLAND JOURNAL OF MEDICINE

American Diabetes Association Standards of Medical Care in Diabetes 2017

(2017) Payal H. Marathe et al.   Journal of Diabetes

Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis

(2017) Kåre I Birkeland et al.   Lancet Diabetes & Endocrinology

Consequences of delaying treatment intensification in type 2 diabetes: evidence from a UK database

(2016) Louise Watson et al.   CURRENT MEDICAL RESEARCH AND OPINION

Intensification of Diabetes Therapy and Time Until A1C Goal Attainment Among Patients With Newly Diagnosed Type 2 Diabetes Who Fail Metformin Monotherapy Within a Large Integrated Health System

(2016) Kevin M. Pantalone et al.   DIABETES CARE

Treatment intensification for patients with type 2 diabetes and poor glycaemic control

(2016) A. Z. Fu et al.   DIABETES OBESITY & METABOLISM

DOES CLINICAL INERTIA VARY BY PERSONALIZED A1C GOAL? A STUDY OF PREDICTORS AND PREVALENCE OF CLINICAL INERTIA IN A U.S. MANAGED-CARE SETTING

(2016) Jay Lin et al.   Endocrine Practice

Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents

(2016) Emanuele Di Angelantonio et al.   LANCET

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Incretin-based drugs for type 2 diabetes: Focus on East Asian perspectives

(2016) Yutaka Seino et al.   Journal of Diabetes Investigation

Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors

(2016) William Polonsky et al.   Patient Preference and Adherence

Meta-analysis of studies examining medication adherence, persistence, and discontinuation of oral antihyperglycemic agents in type 2 diabetes

(2015) Kristy Iglay et al.   CURRENT MEDICAL RESEARCH AND OPINION

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY – CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN – 2015 —EXECUTIVE SUMMARY

(2015) Yehuda Handelsman et al.   Endocrine Practice

Data Resource Profile: Clinical Practice Research Datalink (CPRD)

(2015) Emily Herrett et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

(2015) Marc A. Pfeffer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes

(2015) Bruce A. Perkins et al.   PLoS One

Observational Study on Dipeptidyl Peptidase-4 Inhibitors: A Real-Life Analysis on 360 Patients from the ASL VCO Territory in Italy

(2014) Giuseppe Saglietti et al.   CLINICAL DRUG INVESTIGATION

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2014) Silvio E. Inzucchi et al.   DIABETES CARE

Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin

(2014) M. A. Nauck et al.   DIABETES OBESITY & METABOLISM

Update on developments with SGLT2 inhibitors in the management of type 2 diabetes

(2014) Michael Nauck   Drug Design Development and Therapy

Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action

(2014) Yoshihito Fujita et al.   Journal of Diabetes Investigation

Clinical Inertia in People With Type 2 Diabetes: A retrospective cohort study of more than 80,000 people

(2013) K. Khunti et al.   DIABETES CARE

Changes in Insulin Sensitivity and Insulin Secretion with the Sodium Glucose Cotransporter 2 Inhibitor Dapagliflozin

(2013) Sunder Mudaliar et al.   Diabetes Technology & Therapeutics

Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial

(2013) Burkhard Göke et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

(2012) K. Stenlöf et al.   DIABETES OBESITY & METABOLISM

Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial

(2010) E. Ferrannini et al.   DIABETES CARE

Relationship of baseline HbA1cand efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials

(2010) R. A. DeFronzo et al.   DIABETIC MEDICINE

Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes

(2008) J. F. List et al.   DIABETES CARE

10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes

(2008) Rury R. Holman et al.   NEW ENGLAND JOURNAL OF MEDICINE